Title: Targeting the Gut-Brain Axis to Treat Metabolic Disease
Learning Goals:
-
Define the growing landscape of anti-obesity medications
-
Discuss the science driving their production
-
Review some of the clinical data supporting their use
Bio: David A. Harris, MD, FACS, is an Assistant Professor of Surgery in the Division of Minimally Invasive Surgery at the University of Wisconsin–Madison. Dr. Harris is the founder and Principal Investigator of the Wisconsin Surgical Laboratory in Metabolism (WiSLiM), which investigates how metabolic interventions, particularly bariatric surgery, alter organ function, immune biology, and aging. The WiSLiM Labs’ research spans obesity, diabetes, cancer, and Alzheimer’s disease, integrating preclinical models with translational and human studies. Dr. Harris received his MD from the University of Virginia and completed his residency and fellowship training at Brigham and Women’s Hospital, Harvard Medical School.